From GlobeNewswire: 2025-05-31 08:00:00

The Phase III NAPOLI 3 trial reveals a median overall survival of 19.5 months among long-term survivors receiving the Onivyde plus oxaliplatin, fluorouracil, and leucovorin regimen as a first-line therapy for metastatic pancreatic adenocarcinoma. This post-hoc analysis presented at the ASCO Annual Meeting highlights factors associated with long-term survival, including age, tumor location, and metastasis. Pancreatic adenocarcinoma is a challenging cancer with low survival rates, making these findings crucial for understanding treatment outcomes. Dose adjustments and treatment delays were key in enabling patients to stay on treatment longer and achieve high cumulative doses, leading to improved survival rates. Phase III NAPOLI 3 trial reveals long-term survival data for metastatic pancreatic adenocarcinoma patients. Study shows median overall survival of 19.5 months with Onivyde® plus NALIRIFOX regimen. Dose adjustments allowed for extended treatment duration and high cumulative doses of key medications. Ipsen cautions on future outcomes, citing risks like regulatory hurdles, competition, and clinical trial uncertainties. Market conditions, economic factors, and partner reliability also pose challenges. Ipsen emphasizes the unpredictability of drug development success and commercial viability. Patients’ access to effective treatments remains contingent on various factors.



Read more at GlobeNewswire: Late-breaking analysis demonstrates characteristics